We herein report two cases of portal venous gas (PVG) following alpha-glucosidase inhibitor (α-GI) therapy for diabetes mellitus. Anti-diabetic treatment with voglibose was commenced in the first case, while the second case was treated with miglitol. Both patients recovered without intensive treatment after discontinuing the α-GI therapy. α-GI medications may increase internal intestinal tract pressure by releasing carbon dioxide and hydrogen gas, potentially causing pneumatosis cystoides intestinalis (PCI) or PVG. Our experience suggests that α-GI therapy is an important potential cause of portal venous gas that can be treated conservatively.
Introduction
Generally, the presence of portal venous gas (PVG) is an indicator of a serious underlying condition, such as intestinal tract necrosis. It is necessary to immediately identify the cause of PVG because the fatality rate of the condition is high. On the other hand, some cases of PVG resolve spontaneously with conservative follow-up. We herein present two cases of PVG that developed in association with α-GI therapy and resolved without intensive treatment.
Case Report
In the first case, an 80-year-old woman was hospitalized for acute cholecystitis. On admission, she was diagnosed with diabetes mellitus, for which 0.6 mg per day of voglibose treatment was started. Two days after the initiation of treatment with the α-GI, she complained of abdominal distention, discomfort, tenderness and vomiting. An abdominal examination revealed tympanic resonance on percussion, although no severe tenderness or other peritoneal signs were observed. A hematological examination and CT was ordered. The hematological examination revealed a moderately elevated WBC count and C-reactive protein level, although no evidence of organ dysfunction was noted (Table 1) . A CT scan, however, revealed a marked amount of gas in the intrahepatic portal vein (Fig. 1A) , with expansion of the entire small intestine (Fig. 1B) . Furthermore, pneumatosis cystoides intestinalis (PCI) was recognized at the end of the ileum (Fig. 1C) . Based on these CT findings, we tentatively suspected a severe clinical condition, such as strangulated ileus or superior mesenteric artery obstruction, and decided to perform emergency laparotomy. Intraoperatively, there were micro air bubbles near the site of attachment of the mesentery to the ileum, although no enteric ischemia-related changes were observed ( Fig. 2A, B) . Hence, the abdomen was closed without bowel resection. Thereafter, the patient recovered with only conservative treatment and discontinuation of the α-GI therapy. Since this episode, the patient's symptoms have not recurred.
The second case involved a 69-year-old man who was admitted with syncope and treated conservatively for a transient ischemic attack. Our department was consulted due to the sudden occurrence of abdominal pain. An abdominal examination revealed no severe tenderness or distention. Hematological investigations disclosed no serious abnormalities, except for moderate leukocytosis (Table 2) . A CT scan demonstrated significant PVG, as observed in the first case (Fig. 3A) . However, there were no findings suggestive of enteric ischemia or necrosis in the arterial or portal phase of contrast CT, although severe areas of fecal impaction were detected throughout the large intestine (Fig. 3B) . At that time, we confirmed that the patient had no past history of severe illness, except for diabetes mellitus, which had been treated with 150 mg per day of miglitol (an α-GI ) for several years. Suspecting that the PVG was associated with the α-GI, we discontinued the administration of miglitol and
Figure 3. CT scan images in case 2. Portal venous gas (PVG) was clearly visible in the left lobe of the liver on CT scan in case 2 (A). However, in this case, there were no findings of Pneumatosis Cystoides Intestinalis (PCI), although marked fecal impaction was recognized throughout the large intestine (B). Repeat CT scan the following day showed complete disappearance of PVG following conservative treatment and discontinuation of miglitol therapy (C).
closely observed the patient's progress conservatively. The next day, his white blood cell count fell to a normal level, and there were no signs of PVG on CT (Fig. 3C ). Since then, the patient's symptoms have not recurred.
Discussion
The first reported adult case of PVG involved small bowel ischemia resulting from superior mesenteric artery thrombosis (1). Since then, PVG has been reported in relation to a variety of causes. Advances in imaging have increased the rate of diagnosis of PVG secondary to a number of pathophysiologies. The mortality varies according to the cause; bowel ischemia is the most common cause of PVG and is associated with the highest mortality (75-90%) (2, 3) . Although the initial management depends on the underlying cause, surgical intervention with laparotomy tends to be the first-line treatment since the pathogenesis of PVG is often not identifiable. In our first case, because we emphasized the findings of PVG, we decided to perform emergency laparotomy, although there were no severe symptoms on the abdominal examination or in the blood biochemical data, including the results of the arterial blood gas analysis, and no ischemic changes on contrast CT. Furthermore, there were no enteric ischemia-related changes, and we therefore focused on the possibility of side effects associated with the α-GI therapy.
Alpha-glucosidase inhibitors, a type of orally administered antihyperglycemic drugs, competitively inhibit enzymes at the small intestinal brush border responsible for the breakdown of oligosaccharides and disaccharides into monosaccharides suitable for absorption (4) . These drugs act primarily on α-glucosidase, which is predominantly found in the proximal half of the small intestine. The intestinal absorption of carbohydrates is therefore delayed and shifted to more distal portions of the small intestine and colon. This retards glucose entry into the systemic circulation and lowers the postprandial glucose level. α-GIs act locally at the intestinal brush border and are not absorbed (5) .
The primary side effects of α-GI therapy are gastrointestinal symptoms, specifically bloating, abdominal discomfort, diarrhea and flatulence in approximately 20% of patients (6) . The mechanisms underlying these bowel symptoms are thought to involve intestinal gas production via the fermentation of carbohydrates by the intestinal flora. In addition to peristaltic hypofunction associated with diabetes mellitus, this results in an increased intraluminal pressure, thus allowing gas-producing bacteria to further invade the colonic mucosa through breaks in mucosal integrity (7) . In our first case, a CT scan actually showed both PVG and PCI. We hypothesize that the gas in the intestinal tract caused by the α-GI resulted in PCI, while the gas that could not be absorbed through the intestinal mucosa flowed into the portal vein, thereby causing PVG.
In a PubMed search, only 10 reports were identified using the key words "pneumatosis cystoides intestinalis" and "alpha glucosidase inhibitor;" there being no reports obtainable using the key words "portal venous gas" and "alpha glucosidase inhibitor." A search of Japana Centra Revuo Medicina also revealed only three reports (8) (9) (10) , one of which mentioned the coexistence of PCI (10) . Interestingly, all patients recovered with conservative treatment. Our experience suggests that when PVG findings are detected, it is very important to ask the patient about a history of diabetes mellitus, as well as the administration ofα-GIs in those with a positive diabetes history.
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